ResearcherTravera IncActive in the last 2 years

Mark Stevens

Provisional: name at one institution (moderate confidence)As of 11 November 2026

Known by name at one institution; no external author ID yet. Name as it appears in ClinicalTrials.gov.

Their work

Papers: 0
Trials: 2 (principal investigator on 2)
Grants: 0
Collaborators: 2

Papers, trials and grants by year

2022: 1 trial · 2023: none · 2024: 1 trial

Trials 2

Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs Principal investigator NCT04985357 ↗
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) Principal investigator NCT05461430 ↗

Closest collaborators

The 2 strongest of 2 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

Robert Kimmerling · 1 shared trial, 2024
- Trial Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor Sensitivity to Drugs NCT04985357 ↗
Rob Kimmerling · 1 shared trial, 2022
- Trial Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx) NCT05461430 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.